阿德福韦酯联合胸腺肽α1治疗HBeAg阴性慢性乙型肝炎的疗效观察

摘要

目的观察阿德福韦酯(贺维力)联合胸腺肽α1(基泰)治疗HBeAg阴性慢性乙型肝炎的疗效.方法随机将50例HBeAg阴性慢性乙型肝炎患者分为两组，对照组25例单用阿德福韦酯(10mg po qd)治疗，治疗组25例联合胸腺肽α1(1.6mg ih biw)治疗，两组均治疗48周.结果治疗组各个阶段的肝功复常率、HBVDNA阴转率、48周时的HBsAg阴转率均明显高于对照组(P<0.05)，治疗组总有效率明显高于对照组.结论阿德福韦酯联合胸腺肽α1治疗HBeAg阴性慢性乙型肝炎可有效提高肝功复常率、HBVDNA及HBsAg阴转率，疗效优于单用阿德福韦酯.%　　Objective Observation of adefovir dipivoxil(PowerPoint) combined with thymosin α in treatment of HBeAg negative chronic hepatitis B. Methods 50 patients with HBeAg negative chronic hepatitis B patients were randomly divided into two groups, 25 cases in the control group only with adefovir dipivoxil(10mg po qd) treatment; 25 cases in the treatment group combined with thymosin α(1.6mg ih biw) treatment,two groups were treated for 48 weeks. Results The treatment group in various stages of liver function recovery, HBVDNA negative rate, the negative rates of HBsAg after 48 weeks were significantly higher than that of control group. Conclusion The treatment of adefovir dipivoxil combined with thymosin α to HBeAg negative chronic hepatitis B can effectively improve liver function recovery, HBVDNA and HBsAg negative rates, which is superior to that of single adefovir.